Life Technologies system utilised in new cancer research

Life Technologies has highlighted the publication of two new scientific research studies of cancer and genetic variation, both of which utilised the company’s technology.

The two research programmes used the firm’s Applied Biosystems SOLiD System for DNA sequencing in order to determine conclusions about the role played by genome variation in future development.

One of these, the results of which are to be published in a paper entitled Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing, hopes to highlight the potential of genetic research in monitoring disease progression.

Kip Miller, president of the genetic systems division for Life Technologies, said this was representative of the potential benefits of the SOLiD System to human healthcare research.

He added: “The affordability and accuracy of the SOLiD System has made genome-wide sequencing a commonplace tool for scientists and it has a real potential to become an integral part of genomic-based health decisions.”

Earlier this month, the science firm announced the development of a new molecular test for Vesivirus 2117, which can be a potential contaminant of mammalian cell cultures.